Synergistic cytotoxic effect of human recombinant tumor necrosis factor alpha combined with dihydroambazone.
Dihydroambazone (DHA) is a water-soluble derivative of the experimental anticancer drug ambazone. In vitro, a combination of DHA and human recombinant tumor necrosis factor alpha (TNF) exerted a strong synergism of cytotoxicity against both mouse melanoma B16K cells and the TNF-sensitive mouse fibroblast line L-M (S). Furthermore, in a colony-forming assay with B16K cells a combination of TNF and DHA inhibited colony-formation much more severely than either drug alone. An increased antiproliferative efficiency was also confirmed in vivo against established subcutaneous melanoma B16 tumors of C57BL/6 mice.
Baumgart
J
J
Academy of Sciences, Central Institute of Microbiology and Experimental Therapy, Jena, Germany.
Gase
K
K
Schulze
W
W
Suehnel
J
J
Gutsche
W
W
Behnke
D
D
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D003114:Colony-Forming Units Assay; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D008935:Mitoguazone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D009368:Neoplasm Transplantation; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000494:pharmacology
D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; C058853:dihydroambazone; D008935:Mitoguazone